Skip to main content

Avillion Chooses BSI’s eClinical Software for its Clinical Operations

BADEN, SWITZERLAND, September 7, 2022 – BSI announces that it has been awarded the contract for the supply of its Clinical Trial Management System (CTMS) to Avillion LLP. Avillion is a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory approval.

Avillion selected the BSI CTMS as they felt it met their objectives of being a modular solution across a broad range of functions required to manage and oversee large and complex trial programs. In addition, the platform provides a flexible solution with a high level of configuration without the need for programming, facilitating optimal support of business needs in the evolving clinical research environment. BSI CTMS also comes with fully integrated eTMF and LMS modules, avoiding the need for clients to purchase and integrate other solutions.

The Avillion Operations Director said “Being a small company, it was essential for us to be able to find a system that was flexible and met our needs, but was also quick and simple to implement and maintain in-house. Having worked closely with BSI to implement the system, we are delighted with the ease at which we have been able to incorporate the BSI CTMS system into our working practices”.

Jan Nielsen, Community Manager, Life Sciences at BSI, commented: “Avillion was not only looking for an eClinical tool, but a software provider that would partner with them to invest in understanding their processes and adapting to specific operational needs. Our Clinical Trial Management System stands out for its great flexibility, something our clients love and value. The collaboration with Avillion proves that BSI can successfully deliver not only to companies working with traditional business models, but also to innovative players bringing change to their industries.”

About Avillion

Avillion offers pharma partners an innovative model providing additional funding and clinical development expertise, to maximise the potential of new and existing assets. Avillion takes on the full clinical and regulatory risk, focusing on the speed and quality of trial execution. Typically supporting programs post proof-of-concept through to registration and with an agnostic approach to therapy area, Avillion prides itself in adding value around operational expertise while being backed by established life science investors.

For more information, please visit:

Download Press Release

Next Best Action:

BSI Life Sciences



Jan Nielsen
BSI Life Sciences Community Manager

+41 58 255 96 22